Areas of research

The CLM's research focuses on the following principal areas:

  • The search for new cognitive or neurofunctional markers of pathological brain aging using different imaging modalities (MRI, PET, EEG, and other experimental contexts). In particular, this research examines:
    • the study of the influence of "non-modular" functions such as attention, executive functions and emotions on language;
    • disorders of writing in normal aging and neurodegenerative diseases (Alzheimer's, Parkinson's, Huntington), the use of a common experimental setting (real-time recording of grapheme-motor and oculomotor movements) to better understand these disorders and improve their therapeutic management.
  • The search for risk factors and etio-pathogenic mechanisms through exploration of massive, multidimensional databases (cognition, imaging, genetics, metabolomics) in conjunction with the Human Brain Project and many external partners (INSERM UMR1214 ToNIC, CATI, Swiss Institute of Bioinformatics).
     
  • In the clinical research project called Alzeye (http://www.alzheimer-synapsis.ch/index-fr.php?frameset=1 ), we use retinal imaging coupled with tear samples to complement the usual cognitive assessment of patients with suspected Alzheimer's disease.  Microvascular brain lesions in  MRI will be correlated with microangiopathy in retina. This project aims at defining new ways to diagnose AD in humans, with correlations with data acquired in mouse models. In patients, we use a new, harmless and quick imaging of retina (new type of optical coherent tomography, OCT) as well as brain MRI and dosages in tears and blood.
  • Study of action semantic disorders in neurodegenerative diseases that affect the motor system (Parkinson’s disease and related syndromes).
  • Provision of innovative technologies designed to compensate handicaps affecting language and memory: the use of virtual reality tools.
  • Phase 2-3 diagnostic and therapeutic clinical trials to promote innovative techniques, therapeutic intervention or new medications to prevent pathological brain aging or slow the progression of confirmed illnesses.

Publications

Learn more

 Last updated on 24/06/2019 at 10:58